

MODIFICATION TO ATE MASTER SETTLEMENT AGREEMENT

This Agreement, dated August 6, 2015, shall be a binding modification to the ATE Master Settlement Agreement, dated August 3, 2015 entered into by and between (i) Bayer HealthCare Pharmaceuticals Inc. (“BHCP”), and (ii) the plaintiffs’ counsel listed in the signature pages hereto under the heading “Negotiating Plaintiffs’ Counsel” (“NPC”) (collectively referred to herein as the “Parties”) (the “Modification”). Only those terms listed in this Modification shall be changed all other terms of the MSA shall remain in full force and effect.

1) The Parties hereby agree that footnote 4 of the MSA shall be modified and shall read as follows:

“Any percentage adjustment upward for an enhancement shall be an adjustment based on the Base Point Award to the individual Claimant and shall not be cumulative. Any percentage adjustment downward shall be computed as follows: (a) the first downward adjustment shall be based on the adjusted or gross Point Award after enhancements have been applied, and (b) any subsequent downward adjustment shall be based on the new or adjusted Point Award in order to avoid downward adjustments resulting in zero points and (c) the largest percentage downward adjustment shall be taken first and in descending sequence thereafter.”

2) The Parties hereby agree that footnote 5 of the MSA shall be modified and shall read as follows:

“Risk Factor Reductions are to be applied sequentially, rather than added together and then applied. This means that if more than one applies, they are applied in sequence to reduce the new or adjusted Point Award. For example, apply -75% for illegal drug use, then apply -30% for BMI, rather than adding them together and reducing by 105%.”

3) No other changes or modifications to the MSA are being made by this Modification.

IN WITNESS WHEREOF, NPC and BHCP have executed this Modification to the ATE Master Settlement Agreement effective as of the Execution Date.


Bayer HealthCare Pharmaceuticals Inc.



August 6, 2015

Bayer HealthCare Pharmaceuticals Inc.

Negotiating Plaintiffs' Counsel



Seth A. Katz

August 6, 2015

Burg Simpson Eldredge Hersh & Jardine, P.C.


40 Inverness Drive East

Englewood, CO 80112

Phone: (303) 792-5595

Fax: (303) 708-0527

yazatenotice@burgsimpson.com



Michael A. London

August 6, 2015

Douglas & London, P.C.

59 Maiden Lane, 6th Floor

New York, NY 10038

Phone: (212) 566-7500

Fax: (212) 566-7501

milondon@douglasandlondon.com

Richard D. Meadow

, 2015

The Lanier Law Firm
126 East 56th Street
New York, NY 10022
Phone: (212) 421-2800
Fax: (917) 546-0464
rdm@lanierlawfirm.com

Daniel S. Robinson

, 2015

Robinson Calcagnie Robinson Shapiro & Davis, Inc.
19 Corporate Plaza Drive
Newport Beach, CA 92660
Phone: (949) 720-1288
Fax: (949) 720-1292
[drobinson@rersd.com](mailto:d Robinson@rersd.com)


Michael M. Weinkowitz

, 2015

Levin Fishbein Sedran & Berman
510 Walnut Street, Suite 500
Philadelphia, PA 19106
Phone: (215) 592-1500
Fax: (215) 592-4663
mweinkowitz@lfsblaw.com



Richard D. Meadow
8/6, 2015

The Lanier Law Firm
126 East 56th Street
New York, NY 10022
Phone: (212) 421-2800
Fax: (917) 546-0464
rdm@lanierlawfirm.com



Daniel S. Robinson
8/6, 2015

Robinson Calcagnie Robinson Shapiro & Davis, Inc.
19 Corporate Plaza Drive
Newport Beach, CA 92660
Phone: (949) 720-1288
Fax: (949) 720-1292
drobenson@rcrsd.com



Michael M. Weinkowitz
8/6, 2015

Levin Fishbein Sedran & Berman
510 Walnut Street, Suite 500
Philadelphia, PA 19106
Phone: (215) 592-1500
Fax: (215) 592-4663
mweinkowitz@lfsblaw.com